Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | KHK | P50053 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11141306 | 0.85 | KHK (0.45) | KHKMEN1KMT2AHTR6HTR2C | |
| SCHEMBL29590229 | 0.84 | GRM4 (0.48) | GRM4MEN1KMT2AALDH1A1ENPP2 | |
| SCHEMBL9082862 | 0.83 | HTR2C (0.46) | KHKALDH1A1PARP1HTR2CHTR2B | |
| SCHEMBL11217206 | 0.74 | KHK (0.62) | KHKMEN1KMT2AHTR2CHTR2B | |
| SCHEMBL21150798 | 0.73 | GPR119 (0.57) | POLB | |
| SCHEMBL21150805 | 0.73 | YAP1 (0.46) | GRM4MEN1KMT2AALDH1A1ENPP2 | |
| SCHEMBL6168114 | 0.71 | TSHR (0.54) | KHKALDH1A1PARP1HTR2CHTR2B | |
| SCHEMBL21150757 | 0.70 | ALDH1A1 (0.39) | GRM4MEN1KMT2AALDH1A1ENPP2 | |
| SCHEMBL151557 | 0.69 | MEN1 (0.56) | MEN1KMT2AALDH1A1ENPP2 | |
| SCHEMBL30658421 | 0.69 | PARP1 (0.49) | PARP1HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | GRM4 918/4885KHK 1982/4885MEN1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.